No Data
No Data
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 33% Though Its Price And Business Still Lag The Industry
BTIG Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $5
Buy Rating Justified by Akebia Therapeutics' Strengthened Dialysis Negotiations and Positive Commercial Prospects
Sector Update: Health Care Stocks Advance Premarket Thursday
Akebia Therapeutics Ends Licensing Deal, Commits to Repayment Plan
Akebia And CSL Vifor Have Terminated The License Agreement Providing For The Payment Of Royalties By Akebia To CSL Vifor On Vafseo (Vadadustat) U.S. Net Product Sales. As A Result, Akebia Regained Full Rights To Sell Vafseo In The U.S.
No Data